PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-02-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-3215PMID 28167507PMCID PMC5511572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deubiquitination and Stabilization of PD-L1 by CSN5.

  2016cited by this paper
• Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

  2016influential reference
• Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

  2016cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• An update on PARP inhibitors—moving to the adjuvant setting

  2015cited by this paper
• CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

  2015cited by this paper
• FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

  2015cited by this paper
• Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.

  2014cited by this paper
• Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer

  2014cited by this paper
• JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression

  2013cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination

  2009cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.

  2006influential reference
• Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients

  2004cited by this paper
• Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• The renaissance of GSK3

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• DNA damage-induced activation of p53 by the checkpoint kinase Chk2.

  2000cited by this paper

• Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer

  2026cites this paper
• Major clinical advances in gynecologic cancer in 2025: from de-escalation strategies to precision therapies beyond BRCA

  2026cites this paper
• Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art

  2026cites this paper
• PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma.

  2026cites this paper
• Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects

  2026cites this paper
• Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.

  2026cites this paper
• Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report

  2025cites this paper
• Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers

  2025cites this paper
• DNA damaging agents boost the transcription of endothelin A receptor in high-grade serous ovarian cancer

  2025cites this paper
• High PARP1 expression is associated with proliferative tumor biology in breast cancer

  2025cites this paper
• Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy

  2025cites this paper
• A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

  2025cites this paper
• Treatment of BRCA 1 mutated breast cancer with a PARP inhibitor and an Immune Checkpoint Inhibitor

  2025cites this paper
• Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma

  2025cites this paper
• MLKL PARylation in the endothelial niche triggers angiocrine necroptosis to evade cancer immunosurveillance and chemotherapy

  2025influential citation
• Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities

  2025cites this paper
• Alterations and correlation between DNA damage and repair response and PD-L1 expression in non-small cell lung cancers

  2025cites this paper
• Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy.

  2025cites this paper
• The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers

  2025cites this paper
• Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives

  2025cites this paper
• PARP inhibition augments immunomodulatory function of mesenchymal stem/stromal cells by promoting STAT1 phosphorylation

  2025cites this paper
• PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

  2025cites this paper
• Neoadjuvant Immunotherapy in Hormone Receptor-Positive Breast Cancer: From Tumor Microenvironment Reprogramming to Combination Therapy Strategies

  2025cites this paper
• PARPs and PARP inhibitors: molecular mechanisms and clinical applications

  2025cites this paper
• Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways.

  2025cites this paper
• Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage

  2025cites this paper
• ‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancer

  2025cites this paper
• Parps in immune response: Potential targets for cancer immunotherapy.

  2025cites this paper
• NAD+ Metabolism Reprogramming Drives SIRT1‐Dependent Deacetylation Inducing PD‐L1 Nuclear Localization in Cervical Cancer

  2025cites this paper
• PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy

  2025cites this paper
• Inhibition of UCH-L1 Enhances Immunotherapy Efficacy in Triple-Negative Breast Cancer by Stabilizing PD-L1.

  2025cites this paper
• Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via Immunotherapy.

  2025cites this paper
• Application of mass cytometry in the immune microenvironment of breast cancer

  2025cites this paper
• The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer

  2025cites this paper
• Dostarlimab and niraparib in primary advanced ovarian cancer.

  2025cites this paper
• The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance.

  2025cites this paper
• Immunotherapy in metastatic prostate cancer

  2025cites this paper
• PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies.

  2025cites this paper
• STK25 Loss Augments Anti‐PD‐1 Therapy Efficacy by Regulating PD‐L1 Stability in Colorectal Cancer

  2025cites this paper
• Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial

  2025cites this paper
• PARP Inhibition Shifts Murine Myeloid Cells Toward a More Tolerogenic Profile In Vivo

  2025cites this paper
• Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.

  2025cites this paper
• PARP inhibitors in gastric cancer: unlocking precision oncology

  2025cites this paper
• Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment.

  2025cites this paper
• Peptide-Based Therapeutic Platforms for Addressing Drug Resistance in Breast Cancer

  2025cites this paper
• Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.

  2025cites this paper
• Carrier-adjuvanted immunostimulator to boost photodynamic immunotherapy by downregulating PD-L1 and impairing ATP hydrolysis

  2025cites this paper
• A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

  2025cites this paper
• Post-translational modifications of proteins: dynamic regulatory network and therapeutic targets of tumor immune escape in pan-cancer.

  2025cites this paper
• RUVBL1-mediated mTORC1 activation drives tumour progression and immune evasion for oral squamous cell carcinoma.

  2025cites this paper
• New progress in imaging diagnosis and immunotherapy of breast cancer

  2025cites this paper
• Understanding DNA and PARP in Cancer: Tackling Inhibitor Resistance.

  2025cites this paper
• Modulating NPC1L1 to Potentiate PARP Inhibitor-Induced Ferroptosis and Immune Response in Triple-Negative Breast Cancer

  2025cites this paper
• Immunotherapy in breast cancer: current landscape and emerging trends

  2025cites this paper
• A Promising Druggable Target for Translational Therapy of Ovarian Cancer: A Molecular Profiling of Therapeutic Innovations, Extracellular Vesicle Acquired Resistance, and Signaling Pathways.

  2025cites this paper
• Research progress in bifunctional small molecules for cancer immunotherapy.

  2025cites this paper
• Poly (ADP-ribose) polymerase inhibitors in cancer therapy

  2025cites this paper
• Inflammation and tumor immune escape in response to DNA damage.

  2025cites this paper
• Exploring the Therapeutic Potential of BRCA1 and BRCA2 as Targets in Canine Oncology: A Comprehensive Review of Their Role in Cancer Development and Treatment

  2025cites this paper
• Immunomodulatory mechanisms driving tumor escape in Glioblastoma: the central role of IDO and tryptophan metabolism in local and systemic immunotolerance.

  2025cites this paper
• Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy

  2025cites this paper
• PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research.

  2025cites this paper
• DNA repair at the crossroads of tumor immunogenicity and cancer therapy: Harnessing innate and adaptive immune pathways for improved therapeutic outcomes.

  2025cites this paper
• Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis

  2025cites this paper
• Parabacteroides distasonis promotes CXCL9 secretion of tumor-associated macrophages and enhances CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in non-small cell lung cancer mice

  2025cites this paper
• Olaparib Combined with Anti-PD1 Enhances Immunotherapy of Gastric Cancer Via NF-κB/c-Myc/PD-L1 Signaling

  2025cites this paper
• Drug discovery in advanced and recurrent endometrial cancer: Recent advances

  2025cites this paper
• Self-promoted tumor-targeting nanomedicine activates STING-driven antitumor immunity via photodynamic DNA damage and PARP inhibition

  2025cites this paper
• Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations

  2025cites this paper
• Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

  2025cites this paper
• Clinical approaches to overcome PARP inhibitor resistance

  2025cites this paper
• PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer

  2025cites this paper
• PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer

  2025cites this paper
• Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer

  2025cites this paper
• Elucidating DNA Damage-Dependent Immune System Activation

  2025cites this paper
• Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies

  2025cites this paper
• A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer

  2025cites this paper
• Targeting hormone-related signals to reprogram the antitumor immune response in breast cancer: Research progress and application prospects.

  2025cites this paper
• Progress in the immune microenvironment of prostate cancer and new immunotherapy strategies

  2025cites this paper
• Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades

  2025cites this paper
• Targeting HDAC and PARP Enhances STING‐Dependent Antitumor Immunity in STING‐Deficient Tumor

  2025cites this paper
• Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance

  2025cites this paper
• Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies

  2025cites this paper
• Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study

  2025cites this paper
• The emerging role of PARP inhibitors in prostate cancer: A narrative review.

  2025cites this paper
• Emerging Systemic Therapy Considerations for Pancreatic Cancer.

  2025cites this paper
• JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction

  2025cites this paper
• Targeting PIN1 in Pancreatic Tumor Microenvironment with Peptide Amphiphiles Unleashes Immune Checkpoint Therapy

  2025cites this paper
• Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa

  2025cites this paper
• Kinome-Wide Screening Identifies FAK as a Novel Post-Translational Regulator of PD-L1 Stability and Immune Evasion in Triple-Negative Breast Cancer

  2025cites this paper
• PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells.

  2025cites this paper
• PARPs in tumor immunology: Signal transduction and combination therapy for the future

  2025cites this paper
• Effects of nucleic acid metabolism on prognosis and immune invasion of triple-negative breast cancer

  2025cites this paper
• Chemotherapy-free combination strategies in recurrent platinum-resistant ovarian cancer: promise, evidence and perspectives

  2025cites this paper
• Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

  2025cites this paper
• Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations

  2025cites this paper
• A comprehensive review of current therapeutic strategies in cancers targeting DNA damage response mechanisms in head and neck squamous cell cancer.

  2024cites this paper
• The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design.

  2024cites this paper
• Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer.

  2024cites this paper